PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation

Nemanja Rodic, Robert A. Anders, James R. Eshleman, Ming Tseh Lin, Haiying Xu, Jung H. Kim, Katie Beierl, Shuming Chen, Brandon S. Luber, Hao Wang, Suzanne LTopalian, Drew M. Pardoll, Janis M. Taube

Research output: Contribution to journalArticlepeer-review

Abstract

PD-L1 expression in melanoma correlates with response to PD-1 pathway-blocking antibodies. Aberrant tumor-cell PD-L1 expression may be oncogene driven and/or induced by IFNγ. Melanomas express PD-L1 in association with tumor-infiltrating lymphocytes (TIL), but the potential contribution of the BRAF V600E mutation (BRAFmut) to induced PD-L1 expression has not been determined. Fifty-two archival melanocytic lesions were assessed for PD-L1 expression, TIL infiltration, and BRAFmut simultaneously. IFNγ-induced PD-L1 expression in cultured melanomas was assessed in parallel according to BRAF status. Melanocyte PD-L1 expression was observed in 40% of specimens, and BRAFmut was observed in 42% of specimens, but no significant concordance was found between these variables. Almost all melanocytes displaying PD-L1 expression were observed to be adjacent to TILs, irrespective of BRAF status. TIL- lesions were not more likely to be associated with BRAFmut, when compared with TIL+ lesions. Baseline expression of PD-L1 by melanoma cell lines was virtually nil, regardless of BRAFmut status, and the intensity of IFN-induced PD-L1 expression in melanoma cell lines likewise did not correlate with BRAF mutational status. PD-L1 expression in melanocytic lesions does not correlate with the BRAFmut. Thus, distinct populations of melanoma patients will likely benefit from BRAF inhibitors versus PD-1 pathway blockade.

Original languageEnglish (US)
Pages (from-to)110-115
Number of pages6
JournalCancer Immunology Research
Volume3
Issue number2
DOIs
StatePublished - Feb 2015

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Fingerprint Dive into the research topics of 'PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation'. Together they form a unique fingerprint.

Cite this